Chitosan-based nanocarriers: Effective vehicles for mucosal protein delivery

Chitosan: Manufacture, Properties and Usage

Volumn , Issue , 2011, Pages 365-412

  Braz, Luis ^a   Dionísio, Marita ^a   Grenha, Ana ^a  

^a UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875852625     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (145)

1. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomedicine and Pharmacotherapy 2004;58:168-72.
2. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Critical Reviews in Therapeutic Drug Carrier Systems 2002;19:425-98.
3. Smith PL. Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery. Journal of Controlled Release 1997;46:99-106.
4. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Advanced Drug Delivery Reviews 2001;47:83-97.
5. de la Fuente M, Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine 2008;3:845-57.
6. Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods. Current Opinion in Biotechnology 2001;12:212-9.
7. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Advanced Drug Delivery Reviews 2001;47:39-54.
8. Silva GA, Coutinho OP, Ducheyne P, Shapiro IM, Reis RL. Starch-based microparticles as carriers for the release of active platelet-derived growth factor. Tissue Engineering 2007;13:1259-68.
9. Csaba N, Garcia-Fuentes M, Alonso MJ. The performance of nanocarriers for transmucosal drug delivery. Expert Opinion in Drug Delivery 2006;3(4):463-78.
10. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharmaceutical Research 1996; 13(12):1838-45.
11. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the art grastrointestinal mucosa: quantitation and particle size dependency. Journal of Pharmacy and Pharmacology 1990;42:821-6.
12. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. Journal of Cellular Biochemistry 2006;97:1184-90.
13. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. International Journal of Pharmaceutics 1992;78:43-8.
14. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharmaceutical Research 1994;11: 1358-61.
15. Schipper NGM, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharmaceutical Research 1996;13(11):1686-92.
16. Schipper NGM, Varum KM, Stenberg P, Ocklind G, Lennernas H, Artursson P. Chitosans as absorption enhancers of poorly absorbable drugs 3: influence of mucus on absorption enhancement. European Journal of Pharmaceutical Sciences 1999;8:335-43.
17. Hirano S, Seino H, Akiyama Y, Nonaka I. Biocompatibility of chitosan by oral and intravenous administrations. Polymer Materials and Science Engineering 1988;59:897-901.
18. Ohya Y, Shiratani M, Kobayashi H, Ouchi T. Release behaviour of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity. Pure Applied Chemistry 1994;A31:629-42.
19. Liu H, Chen B, Mao Z, Gao C. Chitosan nanoparticles for loading of toothpaste actives and adhesion on tooth analogs. Journal of Applied Polymer Sciences 2007;106(6):4248-56.
20. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. International Journal of Pharmaceutics 2002;249:101-8.
21. Erbacher P, Zou S, Bettinger T, Steffan A-M, Remy J-S. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharmaceutical Research 1998;15(9):1332-9.
22. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharmaceutical Research 1997;14:1431-6.
23. Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids and Surfaces B-Biointerfaces 2006;53:193-202.
24. Sarmento B, Martins S, Ribeiro A, Veiga F, Neufeld R, Ferreira D. Development and comparison of different nanoparticulate polyelectrolyte complexes as insulin carriers. Internation Journal of Peptide Research and Therapeutics 2006;12(2):131-8.
25. Grenha A, Gomes ME, Rodrigues M, Santo VE, Mano JF, Neves NM, et al. Development of new chitosan/carrageenan nanoparticles for drug delivery applications. Journal of Biomedical Materials Research-part A 2010;92(4):1265-72.
26. Du J, Sun R, Zhang S, Govender T, Zhang LF, Xiong CD, et al. Novel polyelectrolyte carboxymethyl konjac glucomannan-chitosan nanoparticles for drug delivery. Macromolecular Rapid Communications 2004;25:954-8.
27. Pan Y, Ying-jian L, Zhao H, Zheng J, Xu H, Wei G, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. International Journal of Pharmaceutics 2002;249:139-47.
28. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharmaceutical Research 1999;16:1576-81.
29. Al-Qadi S, Grenha A, Seijo B, Goycoolea F, Alonso MJ, Remunan-Lopez C. Chitosan nanoparticle-based inhalable dry powders for protein lung delivery: in vivo evaluation of microencapsulated insulin-loaded nanoparticles in rats. Advances in Chitin Science; Venice 2009.
30. Singh R, Lillard JrJ. Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology 2009;86:215-23.
31. Elsabee MZ, Morsi RE, Al-Sabagh AM. Surface active properties of chitosan and its derivatives. Colloids and Surfaces B-Biointerfaces 2009;74(1):1-16.
32. Mourya VK, Inamdar NN. Trimethyl chitosan and its applications in drug delivery. Journal of Materials Science: Materials in Medicine 2009;20(5):1057-79.
33. Alves NM, Mano JF. Chitosan derivatives obtained by chemical modifications for biomedical and environmental applications. International Journal of Biological Macromolecules 2008;43:401-14.
34. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances in chitosan-based micro-and nanoparticles in drug delivery. Journal of Controlled Release 2004;100:5-28.
35. Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides. Expert Opinion in Drug Delivery 2005;2(5).
36. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Advanced Drug Delivery Reviews 2010; 62(1):28-41.
37. Bonferoni MC, Sandri G, Rossi S, Ferrari F, Caramella C. Chitosan and its salts for mucosal and transmucosal delivery. Expert Opinion in Drug Delivery 2009;6(9):923-39.
38. Masotti A, Ortaggi G. Chitosan micro-and nanospheres: fabrication and applications for drug and DNA delivery. Mini Reviews in Medicinal Chemistry 2009;9(4):463-9.
39. Lee VHL, Yang JJ. Oral drug delivery. In: Hillery A, Lloyd A, Swarbrick J, editors. Drug delivery and targeting: for pharmacists and pharmaceutical scientists. 1 ed. London: Taylor and Francis; 2001. p. 145-83.
40. Hoogstraate JA, Benes L, Burgaud S, Horriere F, Seyler I. Oral trans-mucosal drug delivery. In: Hillery A, Lloyd A, Swarbrick J, editors. Drug delivery and targeting. for pharmacists and pharmaceutical scientists. 1 ed. London: Taylor and Francis; 2001. p. 185-206.
41. Davis SS. Delivery of peptide and non-peptide drugs through the respiratory tract. PSTT 1999;2(11):450-6.
42. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosanpolyethylene oxide nanoparticles as protein carriers. Journal of Applied Polymer Sciences 1997;63:125-32.
43. Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization. Pharmaceutical Research 1999;16:1830-5.
44. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carriers. Journal of Controlled Release 2001;74:317-23.
45. Tian XX, Groves MJ. Formulation and biological activity of antineoplastic proteoglycans derived from Mycobacterium vaccae in chitosan nanoparticles. Journal of Pharmacy and Pharmacology 1999;51:151-7.
46. Bodmeier R, Chen HG, Paeratakul A. A novel approach to the oral delivery of microor nanoparticles. Pharmaceutical Research 1989;6:413-7.
47. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Advanced Drug Delivery Reviews 2010;62:83-99.
48. Kissel T, Maretscheck S, Packhauser C, Schnieders J, Seidel N. Microencapsulation techniques for parenteral depot systems and their application in the pharmaceutical industry. In: Benita S, editor. Microencapsulation: methods and industrial applications. 2 ed. New York: Taylor and Francis; 2006. p. 99-122.
49. Poncelet D. Microencapsulation: fundamentals, methods and applications. In: Blitz JP, Gun'ko VM, editors. Surface chemistry in biomedical and environmental science. Dordrecht: Springer; 2005. p. 23-34.
50. Hu Y, Jiang X, Ding Y, Ge H, Yuan Y, Yang C. Synthesis and characterization of chitosan-poly(acrylic acid) nanoparticles. Biomaterials 2002;23:3193-201.
51. Avadi MR, Sadeghi AMM, Mohammadpour N, Abedin S, Atyabi F, Dinarvand R, et al. Preparation and characterization of insulin nanoparticles using chitosan and arabic gum with ionic gelation method. Nanomedicine: Nanotechnology, Biology and Medicine 2010;6:58-63.
52. Lin Y-H, Mi F-L, Chen C-T, Chang W-C, Peng S-F, Liang H-F, et al. Preparation and characterisation of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 2007;8:146-52.
53. Lin Y-H, Sonaje K, Lin KM, Juang J-H, Mi F-L, Yang H-W, et al. Multi-ioncrosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. Journal of Controlled Release 2008;132:141-9.
54. Bayat A, Larijani B, Ahmadian S, Junginger HE, Rafiee-Tehrani M. Preparation and characterization of insulin nanoparticles using chitosan and its quaternized derivatives. Nanomedicine: Nanotechnology, Biology and Medicine 2008;4:115-20.
55. Zhang H, Oh M, Allen C, Kumacheva E. Monodisperse chitosan nanoparticles for mucosal drug delivery. Biomacromolecules 2004;5(6):2461-8.
56. Huang M, Khor E, Lim L-Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharmaceutical Research 2004;21(2):344-53.
57. Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. International Journal of Pharmaceutics 2003;250(1):215-26.
58. Carvalho ELS, Grenha A, Remunan-Lopez C, Alonso MJ, Seijo B. Mucosal delivery of liposome-chitosan nanoparticle complexes. In: Duzgunes N, editor. Methods in Enzymology. Burlington: Academic Press; 2009. p. 289-312.
59. Tiyaboonchai W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan University Journal 2003;11(3):51-66.
60. Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. International Journal of Pharmaceutics 2006;325:147-54.
61. Sajeesh S, Sharma CP. Novel pH responsive polymethacrylic acid-chitosanpolyethylene glycol nanoparticles for oral peptide delivery. Journal of Biomedical Materials Research-part B: Applied Biomaterials 2006;76B:298-305.
62. Berthold A, Cremer K, Kreuter J. Preparation and characterisation of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for antiinflammatory drugs. Journal of Controlled Release 1996;39:17-25.
63. Alonso MJ. Nanoparticulate drug carrier technology. In: Cohen S, Bernstein H, editors. Microparticulate systems for the delivery of proteins and vaccines.New York: Marcel Dekker; 1996. p. 203-42.
64. Chiellini F, Piras AM, Errico C, Chiellini E. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine 2008;3(3):367-93.
65. Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009;30:2329-39.
66. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 2007;8(10):3054-60.
67. Slutter B, Plapied L, Fievez V, Alonso-Sande M, des Rieux A, Schneider Y-J, et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. Journal of Controlled Release 2009;138:113-21.
68. Mann JF, Acevedo R, Campo JD, Perez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Review of Vaccines 2009;8(1):103-12.
69. Ma Z, Yeoh HH, Lim L-Y. Formulation pH modulates the interaction of insulin with chitosan nanoparticles. Journal of Pharmaceutical Sciences 2002;91(6):1396-404.
70. Ma Z, Lim TM, Lim L-Y. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. International Journal of Pharmaceutics 2005;293:271-80.
71. Lowe PJ, Temple CS. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. Journal of Pharmacy and Pharmacology 1994;46(7):547-52.
72. Behrens I, Vila-Pena AI, Alonso MJ, Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharmaceutical Research 2002;19(8):1185-93.
73. Cuna M, Alonso-Sande M, Remunan-Lopez C, Pivel JP, Alonso-Lebrero JL, Alonso MJ. Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. Journal of Nanoscience and Nanotechnology 2006; 6(9-10):2887-95.
74. Du J, Zhang S, Sun R, Zhang LF, Xiong CD, Peng YX. Novel polyelectrolyte carboxymethyl Konjac glucomannan-chitosan nanoparticles for drug delivery. II. Release of albumin in vitro. Journal of Biomedical Materials Research-part B: Applied Biomaterials 2005;72B:299-304.
75. Sadeghi AMM, Dorkoosh FA, Avadi MR, Saadat P, Rafiee-Tehrani M, Junginger HE. Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods. International Journal of Pharmaceutics 2008;355:299-306.
76. Elsayed A, Remawi MA, Qinna N, Farouk A, Badwan A. Formulation and charaterization of an oily-based system for oral delivery of insulin. European Journal of Pharmaceutics and Biopharmaceutics 2009;73:269-79.
77. Bhumkar DR, Joshi HM, Sastry M, Pokharkar VB. Chitosan reduced gold nanoparticles as movel carriers for transmucosal delivery of insulin. Pharmaceutical Research 2007; 24(8):1415-26.
78. Le Buanec H, Vetu C, Lachgar A, Benoit MA, Gillard J, Paturance S, et al. Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes. Biomedical Pharmacotherapy 2001;55:316-20.
79. Borges O, Borchard G, Verhoef JC, Sousa A, Junginger HE. Preparation of coated nanoparticles for a new mucosal vaccine delivery systems. International Journal of Pharmaceutics 2005;229:155-66.
80. Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, de Sousa A, Borchard G, et al. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. Journal of Controlled Release 2006; 114:348-58.
81. Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. European Journal of Pharmaceutical Sciences 2007;32:278-90.
82. Jain S, Sharma RK, Vyas SP. Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization. Journal of Pharmacy and Pharmacology 2006;58:303-10.
83. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. Journal of Pharmacy and Pharmaceutical Sciences 1998;1:15-30.
84. Senel S, Hincal AA. Drug permeation enhancement via buccal route: possibilities and limitations. Journal of Controlled Release 2001;72:133-44.
85. Madhav NVS, Shakya AK, Shakya P, Singh K. Orotransmucosal drug delivery systems: A review. Journal of Controlled Release 2009;140:2-11.
86. Senel S. potential applications of chitosan in oral mucosal delivery. Journal of Drug Delivery Science and Technology 2010;20(1):23-32.
87. McElnay JC, Hughes CM. Drug delivery-buccal route. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology.New York: Marcel Dekker; 2002. p. 800-10.
88. Hoogstraate JA, Wertz PW. Drug delivery via the buccal mucosa. Pharmaceutical Science and Technology Today 1998;1(7):309-16.
89. Portero A, Remunan-Lopez C, Nielsen HM. The potential of chitosan in ehnancing peptide and protein absorption across the TR146 cell culture model-an in vitro model of the buccal epithelium. Pharmaceutical Research 2002;19:169-74.
90. Sandri G, Poggi P, Bonferoni MC, Rossi S, Ferrari F, Caramella C. Histological evaluation of buccal penetration enhancement properties of chitosan and trimethyl chitosan. Journal of Pharmacy and Pharmacology 2006;58:1327-36.
91. Teijeiro-Osorio D, Remunan-Lopez C, Nielsen HM. Comparative studies of chitosan nanoparticles and molecules in Calu-3 and TR146 cells. Proceedings of the 32nd annual meeting and exposition of the controlled release society. Miami 2005 p. 378.
92. De Campos A, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. International Journal of Pharmaceutics 2001;224:159-68.
93. Sarmento B, Ferreira DC, Jorgensen L, van de Weert M. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2007;65:10-7.
94. Reis CP, Neufeld R, Ribeiro A, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine: Nanotechnology, Biology and Medicine 2006;2:53-65.
95. Illum L. Nasal drug delivery: new developments and strategies. Drug Discovery Today 2002;7(23):1184-9.
96. Lansley AB, Martin GP. Nasal drug delivery. In: Hillery A, Lloyd A, Swarbrick J, editors. Drug delivery and targeting. For pharmacists and pharmaceutical scientists. New York: Taylor and Francis; 2001. p. 237-68.
97. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharmaceutical World Sciences 2004;26:137-42.
98. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discovery Today 2002;7(18):967-75.
99. Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules 2009;14(9):3754-79.
100. Jadhav KR, Gambhire MN, Shaikh IM, Kadam VJ, Pisal SS. Nasal drug delivery system-factors affecting and applications. Current Drug Therapy 2007;2(1):27-38.
101. Marttin E, Verhoef JC, Romeijn SG, Merkus FWHM. Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharmaceutical Research 1995;12(8):1151-7.
102. Fernandez-Urrusuno R, Romani D, Calvo P, Vila-Jato JL, Alonso MJ. Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. S T P Pharma Sciences 1999;9:429-36.
103. Davis SS. Nasal vaccines. Advanced Drug Delivery Reviews 2001;51:21-42.
104. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Advanced Drug Delivery Reviews 2001;51:81-96.
105. Illum L. Transport of drugs from the nasal cavity to the central nervous system. European Journal of Pharmaceutical Sciences 2000;11:1-18.
106. Reddy JS, Venkateswarlu V. Novel delivery systems for drug targeting to the brain. Drugs of the Future 2004;29(1):63-83.
107. Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 2009;10:243-9.
108. Goycoolea F, Lollo G, Remunan-Lopez C, Quaglia F, Alonso MJ. Chitosan-alginate blended nanoparticles as carriers for the transmucosal delivery of macromolecules. Biomacromolecules 2009;10:1736-43.
109. Yu S, Zhao Y, Wu F, Zhang X, Lu W, Zhang H, et al. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. International Journal of Pharmaceutics 2004; 281(1-2):11-23.
110. Merkus FW, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PHM, Hermens WAJJ, et al. Cyclodextrins in nasal drug delivery. Advanced Drug Delivery Reviews 1999;36: 41-57.
111. Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery-A promising option for orally less efficient drugs. Journal of Controlled Release 2006; 114:15-40.
112. Tonnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Development and Industrial Pharmacy 2002;28(6):621-30.
113. Smith J, Wood E, Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharmaceutical Research 2004;21(1):43-9.
114. Shao Z, Krishnamoorthy R, Mitra AK. Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharmaceutical Research 1992;9:1157-63.
115. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, et al. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharmaceutical Research 2002;19(7):998-1008.
116. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. Journal of Controlled Release 2002;78:15-24.
117. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Vila-Jato JL, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. European Journal of Pharmaceutics and Biopharmaceutics 2004;57:123-31.
118. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intransal vaccine delivery. Pharmaceutical Research 2004;21(4):671-4.
119. Borges O, Cordeiro-da-Silva A, Tavares J, Santarem N, de Sousa A, Borchard G, et al. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2008;69:405-16.
120. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. European Journal of Pharmaceutics and Biopharmaceutics 2008;70:735-40.
121. Patton JS, Platz RM. Pulmonary delivery of peptides and proteins for systemic action. Advanced Drug Delivery Reviews 1992;8:179-96.
122. Suzuki M, Machida M, Adachi K, Otabe K, Sugimoto T, Hayashi M, et al. Histopathological study of the effects of a single intratracheal instillation of surface active agents on lung in rats. Journal of Toxicological Science 2000;25:49-55.
123. Yamamoto A, Okumura S, Fukuda Y, Fukui M, Takahashi K, Muranishi S. Improvement of the pulmonary absorption of (Asul,7)-eel calcitonin by various absorption enhancers and their pulmonary toxicity in rats. Journal of Pharmaceutical Sciences 1997;86(10):1144-7.
124. Clark A. Formulation of proteins and peptides for inhalation. Drug Delivery Systems and Science 2002;2(3):73-7.
125. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. Journal of Applied Physiology 1998;84:379-85.
126. Okamoto H, Todo H, Iida K, Danjo K. Dry powders for pulmonary delivery of peptides and proteins. Kona 2002;20:71-83.
127. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 f{hook}Êm. Journal of Aerosol Sciences 1986; 17:811-25.
128. Taylor G, Kellaway I. Pulmonary drug delivery. In: Hillery A, Lloyd A, Swarbrick J, editors. Drug delivery and targeting. For pharmacists and pharmaceutical scientists. New York: Taylor and Francis; 2001. p. 269-300.
129. Cryan S-A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS Journal 2005;7(1):E20-E41.
130. Schurch S, Gehr P, Im Hof V, Geiser M, Green FHY. Surfactant displaces particles toward the epithelium in airways and alveoli. Respiratory Physiology 1990;80:17-32.
131. Makino K, Yamamoto H, Higuchi K, Harada N, Ohshima H, Terada H. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids and Surfaces B-Biointerfaces 2003; 27:33-9.
132. Huang M, Zengshuan M, Khor E, Lim L-Y. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharmaceutical Research 2002;19(10):1488-94.
133. Dailey LA, Kleemann E, Wittmar M, Gessler T, Schmehl T, Roberts C, et al. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharmaceutical Research 2003;20(12):2011-20.
134. Mo Y, Lim L-Y. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. Journal of Pharmaceutical Sciences 2004;93(1):20-8.
135. Finlay WH, Gehmlich MG. Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. International Journal of Pharmaceutics 2000;210:83-95.
136. Finlay WH, Stapleton KW, Zuberbuhler P. Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols. Journal of Aerosol Sciences 1997;28:1301-9.
137. Desai TR, Hancock REW, Finlay WH. Delivery of liposomes in dry powder form: aerodynamic dispersion properties. European Journal of Pharmaceutical Sciences 2003;20:459-67.
138. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharmaceutical Research 1998;15:1748-52.
139. Tsapis N, Bennet D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proceedings of the National Academy of Sciences 2002;99:12001-5.
140. Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. European Journal of Pharmaceutical Sciences 2005;25:427-37.
141. Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. International Journal of Pharmaceutics 2009;381:122-9.
142. Grenha A, Seijo B, Serra C, Remunan-Lopez C. Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterisation. Biomacromolecules 2007;8(7):2072-9.
143. Grenha A, Grainger CI, Dailey LA, Seijo B, Martin GP, Remunan-Lopez C, et al. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. European Journal of Pharmaceutical Sciences 2007;31:73-84.
144. Grenha A, Seijo B, Serra C, Remunan-Lopez C. Surface characterisation of lipid/chitosan nanoparticles assemblies, using X-ray photoelectron spectroscopy and time-of-flight secondary ion mass spectrometry. Journal of Nanoscience and Nanotechnology 2008;8(1):358-65.
145. Grenha A, Seijo B, Carvalho ELS, Remunan-Lopez C. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. European Journal of Pharmaceutics and Biopharmaceutics 2008;69:83-93.